Related Experiment Video
Updated: May 11, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Phosphoproteomic Profiling of Multiple Myeloma Based on Ex Vivo Drug Sensitivity Resistance Testing Identifies
Katie Dunphy1, Ellen Purcell1,2, Caroline A Heckman3
1Department of Biology, Maynooth University, W23 V5XH Kildare, Ireland.
Abstract:
Multiple myeloma (MM) is characterised by the clonal expansion of plasma cells in the bone marrow followed by end-organ damage. Despite a significant increase in the five-year survival rate in recent years, MM is still considered an incurable disease as patients will repeatedly relapse and develop resistance to standard-of-care therapies. A central theme for the personalization of MM therapy is understanding the biological mechanisms of drug resistance and identifying clinically relevant biomarkers of therapeutic response. Highly effective protocols for the enrichment of phosphorylated peptides followed by high-resolution mass spectrometry makes possible the quantitation of thousands of site-specific phosphorylation events, principally on serine, threonine or tyrosine residues. In this study, phosphoproteomic analysis of 20 MM patient cell lysates was performed, stratified based on their ex vivo drug response profiles to Bortezomib and Lenalidomide, two of the most foundational therapeutic agents in the management of MM. In this study, patients who are highly sensitive to these drugs show increased phosphorylation of proteins concerned with translation and RNA processing including the spliceosome, RNA transport and RNA binding pathways, while highly resistant patients demonstrated an increased phosphorylation of proteins involved with tight junctions, the Rap1 signalling pathway and the phosphatidylinositol signalling system. This study has established a phosphoproteomic dataset displaying unique phosphorylation signatures associated with drug sensitivity in MM patient plasma cells. The identification of phosphorylation signatures associated with drug resistance provides the foundation for further exploration of these mechanisms and associated signalling pathways to further characterise drug resistance mechanisms in MM and identify promising biomarkers of therapeutic response and targets for drug re-sensitization in MM.
Insights
This study reveals distinct phosphorylation patterns in multiple myeloma (MM) cells linked to drug sensitivity. Identifying these signatures may lead to new biomarkers for personalized MM therapy and overcoming drug resistance.
Area of Science:
- Oncology
- Proteomics
- Molecular Biology
Background:
- Multiple myeloma (MM) is a plasma cell malignancy with high relapse rates and acquired drug resistance.
- Personalized therapy requires understanding resistance mechanisms and identifying predictive biomarkers.
- Phosphoproteomics enables quantitative analysis of signaling pathway activation.
Purpose of the Study:
- To identify phosphorylation signatures associated with ex vivo drug response in multiple myeloma patient cells.
- To correlate specific phosphorylation patterns with sensitivity or resistance to Bortezomib and Lenalidomide.
- To establish a phosphoproteomic dataset for discovering biomarkers of therapeutic response in MM.
Main Methods:
- Phosphoproteomic analysis of 20 MM patient cell lysates.
- Stratification of patients based on ex vivo drug response to Bortezomib and Lenalidomide.
- High-resolution mass spectrometry for quantitation of site-specific phosphorylation events.
Main Results:
- Highly sensitive MM patients showed increased phosphorylation in translation, RNA processing, spliceosome, RNA transport, and RNA binding pathways.
- Highly resistant MM patients exhibited increased phosphorylation in tight junctions, Rap1 signaling, and phosphatidylinositol signaling pathways.
- Unique phosphorylation signatures were identified correlating with drug sensitivity and resistance in MM patient plasma cells.
Conclusions:
- Phosphorylation signatures are associated with differential drug sensitivity in multiple myeloma.
- These findings provide a foundation for exploring novel biomarkers and therapeutic targets to overcome drug resistance in MM.
- Further research into identified signaling pathways may enhance personalized treatment strategies for MM patients.
More Related Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
12:23Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
Published on: August 2, 2018
